+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of advanced head and neck squamous cell carcinoma with intratumoral cisplatin/epinephrine injectable gel Phase III multicenter studies



Treatment of advanced head and neck squamous cell carcinoma with intratumoral cisplatin/epinephrine injectable gel Phase III multicenter studies



European Journal of Cancer 37(Supplement 6): S102




(PDF emailed within 1 workday: $29.90)

Accession: 035980862

Download citation: RISBibTeXText


Related references

The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Archives of Otolaryngology--Head and Neck Surgery 128(8): 880-885, 2002

Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America. Head and Neck 25(9): 717-731, 2003

Neo-adjuvant chemo- -therapy of advanced squamous-cell head and neck carcinoma A multicenter, phase III, randomized study comparing cisplatin plus 5-fluorouracil with cisplatin plus 5-FU plus recombinant interleukin 2. Cancer Immunology Immunotherapy 47(3): 149-156, 1998

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2. Cancer Immunology, ImmunoTherapy 47(3): 149-156, 1998

A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head and Neck 24(7): 661-669, 2002

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial. Annals of Oncology 6(10): 987-991, 1995

Ifosfamide cisplatin and 13-cis retinoic acid in the treatment of advanced squamous cell carcinoma of the head and neck A phase II study. Proceedings of the American Association for Cancer Research Annual Meeting 40: 190, 1999

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Annals of Oncology 26(9): 1941-1947, 2016

Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck. Results of a phase II Multicenter Study. Cancer 79(7): 1394-1400, 1997

Cisplatin and bleomycin in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck. A randomized facultative Phase III controlled study. Sonderbande Zur Strahlentherapie und Onkologie 81: 141-150, 1987

Phase II study of high-dose ifosfamide as a single agent and in combination with cisplatin in the treatment of advanced and/or recurrent squamous cell carcinoma of head and neck. Oncology (Basel) 50(2): 86-91, 1993

A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck. Cancer 85(4): 952-959, Feb 15, 1999

Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study. European Journal of Cancer 41(9): 1254-1260, 2005

A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer 119(4): 766-773, 2013

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study). Frontiers in Oncology 9: 6, 2019